Active Biotech (ATVBF.PK) and Ipsen presented overall survival, or OS, data from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer, or CRPC.
The intention-to-treat analysis showed median overall survival times of 33.4 vs. 30.4 months in favor of tasquinimod, longer than previously reported in this metastatic prostate cancer population. A stronger trend for survival benefit is observed in patients with bone metastases. This phase II clinical trial was designed to test the safety and efficacy of tasquinimod.
Noteworthy, 41 patients crossed-over from placebo to tasquinimod. Besides, there were imbalances in baseline prognostic factor in favor of the placebo arm. These were addressed with a multivariate analysis of known CRPC prognostic factors. It showed a statistically significant OS advantage for tasquinimod treated patients with a hazard ratio of 0.64, a decrease of around 40% in the instantaneous risk of event (death), accompanied by improvement in progression-free survival.
Click here to receive FREE breaking news email alerts for Active Biotech and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com